60^th Annual Meeting

Abstracts must be submitted online. Complete instructions for submission can be found in the submission portal. The deadline to submit and abstract is Monday, February 3, 2025 at 11:59pm EST (US). No exceptions will be made.

Submission length is limited to 2,500 characters.

Characters in the abstract title, body, and table/image caption will be counted (including spaces). Characters in the author and institution will not be counted. There is a strict limit of one graph, figure, or table to each submitted abstract. No exceptions will be made.

Abstracts which have been previously published or accepted in an English language peer-reviewd journal prior to the abstract submission deadline of February 3, 2025 are NOT eligible for submission.

The Scoliosis Research Society (SRS) must ensure balance, independence, objectivity, and scientific rigor in all educational activities. Therefore, as a person who is in position to influence or control the content of a CME activity, ALL abstract authors must disclose all financial relationships held in the past 24 months with ineligible companies.* If the financial relationship has occurred in the past 24 months, but has since ended, we still require you to disclose the relationship.

SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as "Surgimap, MIMICS, EOS Imaging, ROTEM, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR, etc.," are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners' understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any relevant financial relationships. When there is a known financial relationship, expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Please review the SRS Product Translation Glossary for more information.

All abstracts submitted will be reviewed and graded, in blinded fashion, by the Annual Meeting Scientific Program Committee. To maintain an unbiased review of all abstracts, please do NOT include any identifying information such as researcher, institution, or study group names in your abstract. Inclusion of any identifying information will disqualify your abstract from review.

Two-year follow-up is required for papers submitted to Annual Meeting. Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or three-minute E-Point presentation. Acceptance notification will be sent in May 2025.

By submitting an abstract to the Annual Meeting, abstract authors agree that at least one (1) author will attend the meeting for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. Authors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract's authors will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth may be withdrawn from the program.

All selected authors will be required to respond to a formal invitation by June 5, 2025, to confirm participation in the program.

Authors unable to present their paper in person should inform SRS as soon as possible with a co-author that can attend to present the paper. If no one is able to attend in person, please inform SRS by June 25, 2025, so an alternate paper can be substituted. Please note that in the case of aa "no-show" podium presentation, the presenting author associated with the "no-show" paper will be prohibited from presenting any papers at the next two Annual Meetings.

At least one author or co-author on all E-Point presentations is expected to register to attend the meeting for which they are accepted by the deadline set forth in their acceptance notification. If this author cancels their registration prior to the meeting, the E-Point presentation may be withdrawn from the program.

All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found. Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one-year ban for abstract presentations and a three-year ban for invited speakers and faculty presentations.